Table 3.

Univariate and Mulitvariable Cox Models for the Prediction of Outcomes According to On‐Treatment LVH by Either CP or SL Treated as Time‐Dependent Covariates

Outcomes	CP LVH			SL LVH
	HR	95% CI	P Value	HR	95% CI	P Value
Univariate
MI	1.53	1.25–1.88	<0.001	1.62	1.25–2.10	<0.001
Stroke	1.44	1.21–1.71	<0.001	2.28	1.87–2.10	<0.001
Cardiovascular death	1.80	1.48–2.19	<0.001	2.11	1.69–2.64	<0.001
Composite end point	1.52	1.34–1.71	<0.001	2.00	1.73–2.31	<0.001
All‐cause mortality	1.39	1.21–1.60	<0.001	2.05	1.74–2.43	<0.001
Multivariablea
MI	1.28	1.05–1.49	0.014	1.33	1.14–1.55	0.009
Stroke	1.21	1.07–1.34	0.010	1.69	1.35–2.11	<0.001
Cardiovascular death	1.37	1.11–1.70	0.004	1.53	1.19–1.98	0.001
Composite end point	1.17	1.03–1.34	0.021	1.50	1.27–1.76	<0.001
All‐cause mortality	1.14	1.04–1.33	0.017	1.57	1.30–1.89	<0.001

CI indicates confidence interval; CP, Cornell product; HR, hazard ratio; LVH, left ventricular hypertrophy; SL, Sokolow‐Lyon voltage.

^aAdjusted for randomized treatment, age, sex, prevalent diabetes mellitus, history of stroke, myocardial infarction (MI), ischemic heart disease, heart failure, peripheral vascular disease or prior antihypertensive treatment, baseline serum cholesterol, high‐density lipoprotein cholesterol, glucose and creatinine, and urine albumin/creatinine ratio treated as standard covariates, and on‐treatment heart rate and diastolic and systolic blood pressure treated as time‐varying covariates.